Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
[ Vol. 18 , Issue. 2 ]
Teruhide Yamaguchi* and Eriko UchidaPages 202-208 (7)
Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy. Accordingly, studies are now underway to establish the safety and efficacy of oncolytic viruses.
Oncolytic virus, gene therapy, cancer therapy, replicating virus, genetically modified viruses, clinical safety and efficacy.
Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, Saitama, National Institute of Health Sciences, Kamiyoga 1-18-1, Tokyo
Read Full-Text article